Successful rituximab treatment for severe rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive juvenile dermatomyositis: a case report and literature review

BACKGROUND: Rapidly progressive (RP) interstitial lung disease (ILD) is a life-threatening complication of juvenile dermatomyositis (JDM); however, it is generally refractory to treatment; to the best of our knowledge, no evidence-based treatment has been established for RP-ILD yet. We present the c...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishi, Kentaro, Ogura, Masao, Tamai, Naotaka, Gima, Naofumi, Ide, Kentaro, Koinuma, Goro, Kamei, Koichi, Ito, Shuichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351133/
https://www.ncbi.nlm.nih.gov/pubmed/35927666
http://dx.doi.org/10.1186/s12969-022-00723-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351133/
https://www.ncbi.nlm.nih.gov/pubmed/35927666
http://dx.doi.org/10.1186/s12969-022-00723-5

Ejemplares similares